Current therapies for Alzheimer's disease only treat the symptoms of the disease. We have previously developed a novel monoclonal antibody, 2B3, which binds to the b-secretase cleavage site in amyloid precursor protein (APP) and reduces the production of amyloid-b (Ab) in human cell lines. To determine whether the antibody was likely to be effective in mouse models of amyloid pathology in vivo, we investigated whether 2B3 could also bind to APP in mouse primary cortical neurones. Primary cortical neurones were produced from E15.5-17.5 C57Bl/6 wild-type and transgenic APP/V717I (London mutation) embryos. The percentage of the neuronal population was determined by immunocytochemistry. Cells were treated with 10 lg/ml 2B3 or an irrelevant IgG for 48 h and Ab40 levels determined by ELISA. The population of cells was found to contain over 75% neurones and 2B3 bound effectively to these cells. No differences in Ab40 were detected between wild-type and transgenic cells. Importantly, 2B3 significantly inhibited the production of Ab40 by 75.15±1.37% of the media control, whereas an irrelevant IgG only significantly reduced Ab40 levels by 23.35±5.55% of the media control. The reduction in Ab40 produced by 2B3 was significantly greater than that caused by the IgG. These data indicate that 2B3 binds to APP in mouse neurones and can inhibit Ab40, similar to our previous findings. The antibody is probably therefore acting by steric hindrance of b-secretase and these data suggest that it will be effective in mice in vivo and could be an alternative potential therapy for Alzheimer's disease.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disease for which there are currently only symptomatic treatments available in the UK [1] . Therefore, there is considerable interest in developing therapies that could treat the underlying cause of the disease. The predominant hypothesis to explain the onset of AD is the 'amyloid hypothesis,' which suggests that aggregation of the small peptide, amyloid-b (Ab), into toxic oligomers is an initiating event in the disease, leading to the formation of plaques, intracellular tau-containing tangles, and neuronal loss [2] [3] [4] [5] . Although the amyloid hypothesis has limitations, it does suggest that interfering with the production of Ab from its parent molecule, amyloid precursor protein (APP), should lead to successful therapies. Ab is made from APP by the sequential action of two enzymes, b-secretase, now identified as BACE1 [6] [7] [8] [9] , and the g-secretase complex [6, [10] [11] [12] . We have developed a novel antibody, 2B3, which binds to the b-secretase cleavage site in APP and inhibits the production of Ab by steric hindrance [13] . Having shown that 2B3 acts by inhibiting the activity of b-secretase, it is possible that it could be used as a novel therapeutic agent to treat AD. However, our previous work with 2B3 all involved the use of a human cell line and was carried out in vitro [13] . To determine whether 2B3 is effective in vivo to reduce Ab production, we need to test it in transgenic mouse models of amyloid pathology. However, first, we have to show whether 2B3 can inhibit Ab production in mouse neurones. Therefore, the aim of this study was to investigate whether 2B3 can bind to APP in primary cortical mouse neurones from wild-type mice or transgenic mice expressing the London mutation in human APP (V717I) [14] and then reduce Ab levels. Adult animals with the London mutation mice have levels of human APP two to five times greater than endogenous APP and show increasing levels of Ab over the age of 12 months [14] . Our data clearly show that 2B3 significantly decreased the production of Ab40 in mouse cortical neurones, thus supporting its use in transgenic models of amyloid pathology in vivo.
Materials and methods

Materials and cell culture
All chemicals and reagents were purchased from Sigma-Aldrich (Poole, UK), Life Technologies (Invitrogen, Paisley, UK) or Fisher Scientific (Leicester, UK) and all reactions were performed at room temperature unless otherwise specified.
Antibody production
Complete details of the immunization protocol, hybridoma development and antibody characterization are provided elsewhere [13, 15] . 2B3 was raised to a 15-mer peptide spanning the b-secretase cleavage site on APP, EEISEVKMDAEFRHD. The antibody was concentrated from culture medium using Amicon Centriplus YM-100 filters (Millipore, Watford, UK) with a nominal molecular weight cut-off of 100 kDa and quantified by enzymelinked immunosorbent assay (ELISA) [13, 15] .
Primary cell culture
Animals were allowed free access to food and water and were housed at room temperature (22±21C) with lighting maintained on a 12 : 12 h light-dark cycle. This work complied with the guidelines for the care and use of laboratory animals according to the Animals (Scientific Procedures) Act 1986. The APP(V717I) London mutation [14] was maintained on the inbred C57Bl/6 background. Wild-type C57Bl/6 female mice (Cathays Park Transgenic Production Unit, Cardiff University) were time-mated with heterozygous transgenic APP(V717I) males, a generous gift from Prof. Fred van Leuven (Katholieke Universiteit Leuven, Leuven, Belgium). The females were killed at gestational day E15.5-17.5. Genotyping was carried out on DNA extracted from tail tips using standard methods and the following primers (Eurofins, MWG Operon, Ebersberg, Germany) were used to identify embryos with the APP(V717I) mutation: sense primer 5 0 -CCGATGGG TAGTGAAGCAATGGTT-3 0 and antisense primer 5 0 -TGTGCCAGCCAACAGAGAAAAC-3 0 .
Foetal cortical tissue from both hemispheres was dissected from transgenic V717I and wild-type embryos into Hank's buffered salt solution at 41C, washed and collected by centrifugation. Cells were dissociated from the tissue by incubation with 1 mg/ml trypsin (Worthington, Lakewood, USA) for 20 min at 371C, the action of which was subsequently inactivated by the addition of 1 mg/ml trypsin inhibitor and 50 mg/ml DNAase (Worthington). Cells were spun down and triturated gently in expansion media [Dulbecco's modified eagle's medium (DMEM) and HAM's F12 (1 : 1), supplemented with 1 Â B27 supplement (changed to 1 Â N2 supplement after 1 week in culture), 20 ng/ml fibroblast growth factor, 20 ng/ml epidermal growth factor, 1 U/ml penicillin, 100 mg/ml streptomycin, 1.25 mg/ml Fungizone] and allowed to form neurospheres. Neurospheres were expanded for up to 2 weeks, at which point they were dissociated and differentiated onto 30 000-70 000 kDa poly-L-lysine-coated (20 mg/ml) coverslips in differentiation media [DMEM and HAM's F12 (1 : 1), supplemented with 1 Â B27 supplement, 1% foetal bovine serum and antibiotics as above] at a concentration of 125 000 cells/well of a 24-well plate. All centrifugation steps were performed at 300g, all enzymes were diluted in Hank's buffered salt solution and all tissue from different embryos was maintained separately. Neurones were used 24 h after differentiation.
Immunocytochemistry
Differentiated neurones on coverslips were fixed and processed for immunocytochemistry as described previously [15] . Cells were incubated with antibodies to neurone-specific enolase (NSE, 10 mg/ml; Abcam, Cambridge, UK), glial fibrillary acidic protein (GFAP, 1 mg/ml; Abcam) or 2B3 (10 mg/ml) in blocking solution (0.1 M PBS, 3% serum from the species used to raise the secondary antibody, 1% BSA) overnight at 41C. Antibody labelling was detected using appropriate secondary antibodies conjugated to biotin (1 : 500; Vector Laboratories, Burlingame, California, USA), followed by avidin-FITC (1 : 600, Vector Laboratories). Cover slips were mounted onto glass slides using VECTAS-HIELD HardSet Mounting Medium (Vector Laboratories) with DAPI (1 : 4) and visualized using a Leica DMIRE2 microscope (Leica Microsystems (UK) Ltd, Milton Keynes, UK) and Openlab 4.04 software (Perkin-Elmer, Llantrisant, UK). All images were taken using a 63 Â objective lens.
Effects of 2B3 on levels of Ab40
Differentiated neurones were incubated with control media, 2B3 or an irrelevant control mouse IgG (Sigma-Aldrich) (both at 10 mg/ml) for 48 h at 371C. For analysis of Ab40, media were subjected to immunoprecipitation and ELISA as described previously [13, 15] . Briefly, the ELISA used the N-terminal Ab antibody 6E10 (5 mg/ml) as the capture antibody and affinity-purified BAM401AP (0.45 mg/ml; Autogen Bioclear, Calne, UK), specific to the C-terminus of human Ab40, as the detection antibody. Data were normalized to the total cell protein concentration as determined by the bicinchoninic acid protein assay (Pierce, Rockford, Illinois, USA).
Statistical analysis
Data generated in ELISAs were quantified by comparing data with standard curves included on each plate using Graphpad Prism 4 (GraphPad Software, San Diego, California, USA). Results were first normalized to the total protein concentration, where relevant, expressed as % of media control values and then either compared with the 'hypothetical' control value of 100% or using unpaired Student's t-tests, both at the two-tailed significance level.
Results
Cells from each embryo were maintained and processed separately for all experiments. No significant differences were observed in Ab40 levels between cells from transgenic (2.33±0.58 ng/mg protein, n = 3) and wildtype animals (2.39±0.33 ng/mg protein, n = 4) and APP levels were also similar as observed with immunocytochemical labelling for 2B3 and two commercial Inhibition of amyloid-b in mouse neurones Thomas et al. 1059 anti-APP antibodies detecting the N or C termini of APP, respectively (data not shown). Data for transgenic and wild-type embryos were therefore pooled for the Ab40 ELISAs.
Immunocytochemical staining using NSE as a neuronespecific marker confirmed the presence of a population of differentiated neurones estimated to be over 75% of the cells in the cultures from all embryos (Fig. 1a) . A few cells were stained with GFAP, indicating that they were glial cells (Fig. 1b) . 2B3 labelled many cells in cultures from both wild-type and transgenic embryos (Fig. 1c) . Negative controls were performed for all antibodies by exclusion of the primary antibody and showed no specific staining ( Fig. 1d for 2B3 , data not shown for NSE or GFAP). Images for cells from wild-type and transgenic embryos were similar and therefore only wild-type cells are shown in Fig. 1 .
Administration of 2B3 at 10 mg/ml, a concentration we have previously shown to reduce the production of Ab40 in cells in culture [13] , to primary cortical neurones resulted in a significant 75.15±1.37% (P < 0.0001) reduction from media control. Treatment with the irrelevant IgG produced a much smaller, significant reduction of 23.35±5.55% (P < 0.006) in Ab40 levels compared with media-treated cells (Fig. 2) . Importantly, the reduction in Ab40 produced by 2B3 was significantly different from that caused by the irrelevant IgG (P < 0.0001). Attempts were made to measure Ab42 in the neurones as we have previously shown that 2B3 also affects Ab42 production [13] , but levels were below the detection limit of the ELISA.
Discussion
We have clearly shown that our anti-b-secretase cleavage site antibody, 2B3, can bind to primary mouse cortical neurones and inhibit the production of Ab40. Thus, our antibody should bind to APP in mouse brains in vivo and inhibit the production of Ab40.
We successfully obtained cultures of cortical mouse cells consisting of over 75% neurones. Therefore, it is highly likely that the results we have obtained are predominantly due to the binding of 2B3 to APP in neurones rather than glial cells. However, as glial cells also produce Ab [16] , 2B3 could also have a beneficial effect in reducing Ab made by these cells. Furthermore, we found here that 2B3 can bind to these mouse neurones, showing that the antibody recognizes murine APP as well as human APP in cell lines [13] . We observed no differences in Ab40 or APP levels comparing the wild-type and transgenic embryos. This is because of the lack of Representative examples of immunocytochemistry for NSE, GFAP and 2B3 in mouse primary cortical cultures. (a) Specific labelling of a large population of wild-type neurones with an anti-NSE antibody (10 mg/ml) detected using a biotinylated anti-rabbit antibody (1 : 500) and avidin-FITC (1 : 600). (b) Specific labelling of a small population of wild-type glial cells with an anti-GFAP antibody (1 mg/ml) detected as above. (c) Specific labelling of wild-type cells with 2B3 (10 mg/ml) detected using a biotinylated anti-mouse antibody (1 : 500) and avidin-FITC (1 : 600). (d) Negative control for 2B3 showing low levels of nonspecific staining in wild-type cells incubated in the absence of the primary antibody and detected as above. Similar results were obtained with negative controls for NSE and GFAP (data not shown). Coverslips were mounted with VECTASHIELD mounting medium with DAPI to counterstain the nuclei. n = 5-7. Scale bar = 25 mm. GFAP, glial fibrillary acidic protein; NSE, neurone-specific enolase. activation of the transgene; the Thy1 promoter used in the construct remains inactive until after birth [17] . Therefore, we were able to pool the data from the Ab40 ELISAs for the wild-type and transgenic embryos.
We obtained a large 75% reduction in Ab40 production that was similar to the 63% reduction we have described previously for 2B3 in immortalized human MOG-G-UVW astrocytoma cells [13] . In our other studies with 2B3, we observed no effect of the antibody on non-amyloidogenic cleavage by a-secretase [13] ; thus we believe that it is highly unlikely that this pathway would be affected in the cortical neurones. We therefore propose that 2B3 is likely to be working by the same mechanism of steric hindrance of b-secretase activity that we described previously for the human cells [13] . The small effect of the irrelevant control IgG is likely to be due to the inclusion of this large protein in the incubation media of the cells and provides a control for this possible effect of 2B3. Importantly, the much larger effect of 2B3, and the clear difference between the 2B3 and IgG-treated groups, shows that it is not simply the presence of a monoclonal murine antibody that produces the reduction in Ab40 levels reported here. Clearly, it is essential to have an antibody that can bind to the b-secretase cleavage site [13] . The data we have described here strongly suggest that 2B3 will bind to mouse neurones in the brain and may reduce Ab production in vivo. Since 2B3 binds to endogenous mouse APP, it could be used to investigate the role of APP in normal brain function. Importantly, our results will now allow us to test the efficacy of 2B3 to both reduce Ab levels and to improve cognitive performance in transgenic mouse models of amyloid pathology. Such studies are critical to determine whether this anti-b-secretase cleavage site antibody could be a potential novel therapeutic agent for use in AD patients. Levels of extracellular Ab40 from culture media of primary cortical neurones from wild-type and transgenic APP V717I mouse embryos after incubation with 2B3 or an irrelevant mouse IgG at 10 mg/ml for 48 h. Data are expressed as mean (±SEM) % of media control Ab levels as detected in a sandwich ELISA and corrected for the total cell protein concentration. Data were pooled for wild-type and transgenic embryos. 2B3 significantly reduced Ab40 from media control and the irrelevant IgG. The irrelevant IgG produced a much smaller, significant decrease in Ab levels from the media control. **P < 0.01, ***P < 0.0001, significantly different from the media control (100%); ### P < 0.0001, 2B3 significantly different from IgG with unpaired two-tailed Student's t-tests. n = 7. Ab, amyloid-b; APP, amyloid precursor protein; IgG, immunoglobulin G.
Inhibition of amyloid-b in mouse neurones Thomas et al. 1061 
